These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 90473)

  • 21. Studies on phagocytosis of mucoid and nonmucoid variants of Pseudomonas aeruginosa. I. Induction of homologous immunity by nonmucoid strains of P. aeruginosa.
    Gościniak G; Grzybek-Hryncewicz K
    Arch Immunol Ther Exp (Warsz); 1988; 36(2):177-84. PubMed ID: 2467637
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Prevalence of Pseudomonas aeruginosa O serogroups].
    Ivanova NI; Bekina KE
    Zh Mikrobiol Epidemiol Immunobiol; 1987 Jul; (7):10-3. PubMed ID: 3118618
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Towards serodiagnosis of Serratia marcescens infections: examination of sera from noninfected patients and from experimentally infected rabbits for anti-H and anti-O antibodies; S. marcescens O-antigen cross-reactions with those of other enterobacteriaceae.
    Traub WH
    Zentralbl Bakteriol Mikrobiol Hyg A Med Mikrobiol Infekt Parasitol; 1981 Nov; 250(4):490-6. PubMed ID: 7036590
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Protective properties and haemagglutinins in serum from humans and in serum from mice injected with a new polyvalent Pseudomonas vaccine.
    Jones RJ; Roe EA
    Br J Exp Pathol; 1975 Feb; 56(1):34-43. PubMed ID: 812544
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Application of vaccine technology to prevention of Pseudomonas aeruginosa infections.
    Pier G
    Expert Rev Vaccines; 2005 Oct; 4(5):645-56. PubMed ID: 16221066
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Derivation and experimental evaluation of polyvalent corpuscular vaccine for prevention of infections caused by Pseudomonas aeruginosa. I. Development of polyvalent corpuscular vaccine].
    Moroz AF; Radkevich SA; Antsiferova NG; Brodinova NS
    Zh Mikrobiol Epidemiol Immunobiol; 1981; (8):44-9. PubMed ID: 6171956
    [No Abstract]   [Full Text] [Related]  

  • 27. [[Vaccine development for P. aeruginosa: based on antigen cloning of clinical vaccines][].
    von Specht BU
    Zentralbl Chir; 1999; 124(4):298-302. PubMed ID: 10355084
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunological evaluation of OMP-F of native Iranian Pseudomonas aeruginosa as a protective vaccine.
    Ahmadi H; Tabaraie B; Maleknia S; Pormirzagholi F; Nejati M; Hedayati MH
    J Infect Dev Ctries; 2012 Oct; 6(10):721-6. PubMed ID: 23103894
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pseudomonas aeruginosa strains from nosocomial pneumonia are more serum resistant than P. aeruginosa strains from noninfectious respiratory colonization processes.
    Vitkauskiene A; Scheuss S; Sakalauskas R; Dudzevicius V; Sahly H
    Infection; 2005 Oct; 33(5-6):356-61. PubMed ID: 16258867
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Flagella specific H antigenic schema of Pseudomonas aeruginosa (author's transl)].
    Ansorg R
    Zentralbl Bakteriol Orig A; 1978 Nov; 242(2):228-38. PubMed ID: 104481
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effectiveness of immunization with single and multi-component vaccines prepared from a common antigen (OEP), protease and elastase toxoids of Pseudomonas aeruginosa on protection against hemorrhagic pneumonia in mink due to P. aeruginosa.
    Homma JY; Abe C; Tanamoto K; Hirao Y; Morihara K; Tsuzuki H; Yanagawa R; Honda E; Aoi Y; Fujimoto Y; Goryo M; Imazeki N; Noda H; Goda A; Takeuchi S; Ishihara T
    Jpn J Exp Med; 1978 Apr; 48(2):111-33. PubMed ID: 101698
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Protection against pulmonary infection with Pseudomonas aeruginosa following immunization with P. aeruginosa-pulsed dendritic cells.
    Worgall S; Kikuchi T; Singh R; Martushova K; Lande L; Crystal RG
    Infect Immun; 2001 Jul; 69(7):4521-7. PubMed ID: 11401995
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Somatic antigens of Pseudomonas aeruginosa. The structure of O-specific polysaccharide chains of the lipopolysaccharides from P. aeruginosa O1 (Lányi), O3 (Habs), O13 and O14 (Wokatsch), and the serologically related strain NCTC 8505.
    Knirel YA; Vinogradov EV; Shashkov AS; Wilkinson SG; Tahara Y; Dmitriev BA; Kochetkov NK; Stanislavsky ES; Mashilova GM
    Eur J Biochem; 1986 Mar; 155(3):659-69. PubMed ID: 2420587
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Serological typing of Pseudomonas aerugionosa--grouping of serotypes.
    Terada Y; Sugiyama J; Orikasa M
    Jpn J Exp Med; 1977 Jun; 47(3):203-8. PubMed ID: 72175
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Is there a geographic epidemiology of serogroups O of Pseudomonas aeruginosa?].
    Vieu JF; Allos G; Hassan-Massoud B; Santos-Ferreira MO; Tselentis G
    Bull Soc Pathol Exot Filiales; 1984; 77(3):288-94. PubMed ID: 6207946
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Complex serology and immune response of mice to variant high-molecular-weight O polysaccharides isolated from Pseudomonas aeruginosa serogroup O2 strains.
    Hatano K; Pier GB
    Infect Immun; 1998 Aug; 66(8):3719-26. PubMed ID: 9673254
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Cell-free Pseudomonas vaccine. IV. Laboratory trials of the effectiveness of experimental Pseudomonas vaccines].
    Stanislavskiĭ ES; Joó I; Bulk VF; Zhvanetskaia MI; Mashilova GM
    Zh Mikrobiol Epidemiol Immunobiol; 1982 Oct; (10):25-9. PubMed ID: 6817559
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Production and experimental testing of the polyvalency of corpuscular vaccine for the prevention of Pseudomonas aeruginosa infections II. Experimental testing of the immunogenicity of polyvalent corpuscular Pseudomonas aeruginosa vaccine].
    Moroz AF; Antsiferova NG; Radkevich SA; Mishina VS
    Zh Mikrobiol Epidemiol Immunobiol; 1981 Oct; (10):74-80. PubMed ID: 6800165
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The epidemiology of Pseudomonas aeruginosa and the development of a polyvalent vaccine.
    Pranter W; Staerk J; Zellner R; Zwisler O
    Prog Immunobiol Stand; 1971; 5():414-8. PubMed ID: 4633968
    [No Abstract]   [Full Text] [Related]  

  • 40. Protection against fatal Pseudomonas aeruginosa pneumonia in mice after nasal immunization with a live, attenuated aroA deletion mutant.
    Priebe GP; Meluleni GJ; Coleman FT; Goldberg JB; Pier GB
    Infect Immun; 2003 Mar; 71(3):1453-61. PubMed ID: 12595463
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.